Neil J F, Himmelhoch J M, Licata S M
Arch Gen Psychiatry. 1976 Sep;33(9):1090-2. doi: 10.1001/archpsyc.1976.01770090080007.
In a patient with recurrent episodes of severe mania, classical manifestations of myasthenia gravis developed for the first time during treatment with lithium carbonate. Four episodes were recorded in which the appearance of progressive weakness coincided with subacute or long-term lithium carbonate administration during periods of psychiatric remission. In each instance, neurologic symptoms were ameliorated or disappeared shortly after the drug was discontinued or its dosage was reduced. There was no evidence of lithium carbonate toxicity or electrolyte disturbances at any time during treatment. Based on a literature review of animal studies and related clinical reports, a mechanism of peripherally mediated neuromuscular cholinergic insufficiency is proposed. In addition, the differential diagnosis of muscle weakness during lithium carbonate administration is discussed.
在一名患有重度躁狂复发发作的患者中,重症肌无力的典型表现首次在碳酸锂治疗期间出现。记录到4次发作,其中进行性肌无力的出现与精神症状缓解期的亚急性或长期碳酸锂给药同时发生。在每种情况下,停药或减少药物剂量后不久,神经症状均得到改善或消失。治疗期间任何时候均无碳酸锂毒性或电解质紊乱的证据。基于对动物研究和相关临床报告的文献综述,提出了一种外周介导的神经肌肉胆碱能功能不全的机制。此外,还讨论了碳酸锂给药期间肌肉无力的鉴别诊断。